MECHANISMS OF AUTOANTIBODY PRODUCTION IN SLE
SLE 自身抗体产生机制
基本信息
- 批准号:2837537
- 负责人:
- 金额:$ 21.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-08-01 至 1999-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Antinuclear antibodies are a central feature of SLE and related rheumatic
diseases, and are thought to be directly involved in the pathogenesis of
these disorders. The antigens recognized by these autoantibodies are
generally components of large DNA-protein or RNA-protein particles. It has
been shown that Th clones inducing the production of pathogenic anti-DNA
antibodies are responsive to DNA-histone complexes, but not to either DNA
or histones alone. We have found that autoantibody production and the
activation of autoreactive T cells specific for a chromatin protein can be
triggered by alterations in its quaternary structure induced by the
binding of a viral protein. Thus, the quaternary structure of an
autoantigen may be critical for the presentation of epitopes recognized by
autoreactive T cells. In view of the importance of quaternary structure in
generating autoreactive T cells, it seems worthwhile to characterize the
interactions of autoantigenic chromatin proteins with other self and
nonself antigens. This competitive renewal application will extend our
previous work on the Ku (p70/p80) heterodimer, a nonhistone chromatin
antigen recognized by autoantibodies found in the sera of certain patients
with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and
overlap syndromes. The basis for autoimmunity to this autoantigen in human
disease will also be examined. We hypothesize that the binding of either
foreign antigens or autoantibodies to certain functional domains of Ku or
other antigens may trigger autoimmunity by enhancing the presentation of
cryptic T cell epitopes of self to which tolerance is incomplete. In
Specific Aim 1, the domains of Ku mediating p70-p80 dimerization and
binding to a 350 kDa protein (p350) with DNA-dependent protein kinase
activity will be determined using prokaryotic and eukaryotic expression
systems and specific monoclonal antibodies generated previously in our
laboratory. Parallel studies will address the question of whether the same
domains are involved in interactions with foreign (viral) antigens that
might potentially trigger autoimmunity. In Specific Aim 2, the importance
of these functional domains as targets of autoantibodies in SLE, SSc and
overlap syndrome will be determined. The HLA associations of
autoantibodies to individual epitopes of Ku will be determined, and the
basis for the association of anti-Ku, anti-Su, and anti-RNA polymerase II
autoantibodies in many sera will be explored. Finally, the possibility
that autoantibodies of particular specificities can spread autoimmunity
from one antigen to another by altering antigen processing will be
investigated. Although the latter studies are exploratory in nature, they
may provide direct evidence that the binding of certain autoantibodies,
like some foreign proteins, can trigger autoimmunity by altering the
quaternary structure of an autoantigen.
抗核抗体是 SLE 和相关风湿病的核心特征
疾病,并被认为直接参与疾病的发病机制
这些疾病。这些自身抗体识别的抗原是
通常是大DNA-蛋白质或RNA-蛋白质颗粒的成分。它有
研究表明,Th 克隆可诱导产生致病性抗 DNA
抗体对 DNA-组蛋白复合物有反应,但对任何一种 DNA 都没有反应
或单独的组蛋白。我们发现自身抗体的产生和
特定于染色质蛋白的自身反应性 T 细胞的激活可以
由其四级结构的变化引发
病毒蛋白的结合。因此,四级结构
自身抗原可能对于表位的呈现至关重要
自身反应性T细胞。鉴于四级结构在
产生自身反应性 T 细胞,似乎值得表征
自身抗原染色质蛋白与其他自身和其他蛋白的相互作用
非自身抗原。这项具有竞争力的续订申请将延长我们的
之前关于 Ku (p70/p80) 异二聚体(一种非组蛋白染色质)的工作
某些患者血清中发现的自身抗体识别的抗原
患有系统性红斑狼疮 (SLE)、系统性硬化症 (SSc) 和
重叠综合症。人类对该自身抗原产生自身免疫的基础
疾病也会受到检查。我们假设两者的结合
针对 Ku 或某些功能域的外来抗原或自身抗体
其他抗原可能通过增强抗原的呈递来触发自身免疫
自身的隐性 T 细胞表位,其耐受性不完全。在
具体目标 1,Ku 介导 p70-p80 二聚化的结构域和
通过 DNA 依赖性蛋白激酶与 350 kDa 蛋白 (p350) 结合
将使用原核和真核表达来确定活性
系统和之前在我们的系统中生成的特异性单克隆抗体
实验室。平行研究将解决是否相同的问题
结构域涉及与外来(病毒)抗原的相互作用
可能会引发自身免疫。在具体目标 2 中,重要性
这些功能域作为 SLE、SSc 和 SSc 中自身抗体的靶标
将确定重叠综合症。 HLA 协会
将确定针对 Ku 的各个表位的自身抗体,并且
抗 Ku、抗 Su 和抗 RNA 聚合酶 II 关联的基础
将探索许多血清中的自身抗体。最后,可能性
特定特异性的自身抗体可以传播自身免疫
通过改变抗原加工从一种抗原到另一种抗原将是
调查了。尽管后者的研究本质上是探索性的,但
可以提供直接证据证明某些自身抗体的结合,
像一些外来蛋白质一样,可以通过改变
自身抗原的四级结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WESTLEY H REEVES其他文献
WESTLEY H REEVES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WESTLEY H REEVES', 18)}}的其他基金
Activation of Innate Immunity by Small Ribonucleoprotein
小核糖核蛋白激活先天免疫
- 批准号:
7278714 - 财政年份:2004
- 资助金额:
$ 21.57万 - 项目类别:
Activation of Innate Immunity by Small Ribonucleoprotein
小核糖核蛋白激活先天免疫
- 批准号:
7121670 - 财政年份:2004
- 资助金额:
$ 21.57万 - 项目类别:
Activation of Innate Immunity by Small Ribonucleoprotein
小核糖核蛋白激活先天免疫
- 批准号:
6839619 - 财政年份:2004
- 资助金额:
$ 21.57万 - 项目类别:
Activation of Innate Immunity by Small Ribonucleoprotein
小核糖核蛋白激活先天免疫
- 批准号:
6950446 - 财政年份:2004
- 资助金额:
$ 21.57万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 21.57万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 21.57万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 21.57万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 21.57万 - 项目类别:
Discovery Grants Program - Individual